New research sheds light on role of HPV in head and neck cancers

October 7, 2016
Human Papillomavirus. Credit: Wikimedia Commons

Human Papillomavirus (HPV) drives a greater number of head and neck cancers than previously thought, finds new research from UCL and the University of Southampton.

The findings, published in the Journal of Clinical Oncology, offer valuable insight into the role of HPV in tumour development and explore the possibility of a viable treatment option for specific cancer patients.

HPV affects the skin and the moist membranes that line parts of the body. There are over 100 different types of the virus and the body's immune system is normally able to get rid of an HPV infection without it causing any problems. However,some HPV types are known to cause specific cancers, in particular cervical cancer and tonsil cancers (oropharyngeal cancers).

It is known that in HPV associated (HPV+) oropharyngeal cancer, there's a very strong link between the number of immune cells (T-cells) in the tumour and patient survival - when high numbers of T-cells are present, patients respond well to therapy (either surgery or chemoradiotherpay). When tumours are not caused by the virus (HPV-), far fewer immune cells are present, and patients do not respond as well to treatment. This suggests that the cancers caused by virus are more readily detected by the patients' immune systems, and this intrinsic immune response plays a key role in the better survival of most patients with HPV+ cancers.

So, when the team discovered that HPV was also driving a small percentage of head and neck cancers at sites other than the oropharynx, it seemed likely that these patients would also experience significantly better survival rates. Surprisingly this was not the case.

"When we looked at HPV+ cancers at other head and neck sites, we didn't see the same survival benefit or infiltration of T-cells as we did in the HPV+ tonsil cancers." explains Dr Tim Fenton, Senior Research Associate, UCL Cancer Institute, and senior author of the study. "And we think that this is the major difference in determining the difference in patient prognosis."

So why is there such a marked difference in immune cell numbers in HPV+ oropharyngeal cancer and HPV+ cancers at other sites in the head and neck? The answer may lie in the anatomy of the oropharynx (tonsils).

Dr Fenton says "The tonsils are composed of lymphoid tissue, so there are many already present in this area. There's a possibility that cancers developing in the tonsils are very visible to the immune system in that respect. However, HPV- oropharyngeal cancers contain far fewer T-cells, so it appears to be a combination of having a virally driven cancer that is located in the tonsil that gives a strong immune response, and much better clinical outcome."

"The other important point to take from this study, is that there are HPV-targeted therapeutic vaccines in clinical trials at the moment. In fact the Southampton team are about to open a clinical trial testing one such vaccine (HARE-40 Trial) . Currently, we test oropharyngeal cancers for HPV, but not cancers arising at other sites in the head and neck. Even though numbers of these patients are relatively small - approximately 1 in 25 patients - the likely benefit from vaccination, particularly as these treatments become more fully developed, means that testing should be more widespread for these specific cancers."

Explore further: Incisionless robotic surgery offers promising outcomes for oropharyngeal cancer patients

More information: A. Chakravarthy et al. Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx, Journal of Clinical Oncology (2016). DOI: 10.1200/JCO.2016.68.2955

Related Stories

Incisionless robotic surgery offers promising outcomes for oropharyngeal cancer patients

September 16, 2016
A new study from researchers at Henry Ford Hospital finds an incisionless robotic surgery – done alone or in conjunction with chemotherapy or radiation – may offer oropharyngeal cancer patients good outcomes and survival, ...

Particular HPV strain linked to improved prognosis for throat cancer

September 28, 2016
When it comes to cancer-causing viruses like human papillomavirus, or HPV, researchers are continuing to find that infection with one strain may be better than another.

Study examines link between HPV and risk of head and neck cancers

January 21, 2016
Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck ...

Prognosis of tumors positive for human papilloma virus in head and neck cancers varies according to the site

April 6, 2014
Patients with cancer of the throat and who are positive for the Human Papilloma virus (HPV+) have a good prognosis, but until now the effect of being HPV+ on the prognosis of tumours located elsewhere in the head and neck ...

People with hepatitis C are two to five times more likely to develop certain head and neck cancers

April 13, 2016
Long associated with liver cancer and non-Hodgkin's lymphoma, a study from The University of Texas MD Anderson Cancer Center reveals for the first time that the hepatitis C virus (HCV) is associated with certain head and ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.